Efficacy and safety of Tuina therapy for children with combined allergic rhinitis and asthma syndrome in remission: a randomized controlled trial protocol
Frontiers in Medicine · 23.06.2026 · 13
DOI: 10.3389/fmed.2026.1854540 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Frontiers in Medicine, online erschienen am 23.06.2026. Verfasst von Xin Yun Chia und 14 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Jing'an, Shanghai, China. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background
Combined allergic rhinitis and asthma syndrome (CARAS) is a prevalent chronic respiratory disorder among children, characterized by the coexistence of allergic rhinitis and asthma symptoms, thereby substantially impairing quality of life. Pediatric Tuina, a traditional Chinese manual therapy, has demonstrated potential in the management of pediatric respiratory conditions; however, its effectiveness in treating CARAS remains insufficiently studied.
Objective
This trial aims to assess the clinical efficacy and safety of pediatric Tuina in the treatment of CARAS, with the objective of establishing an effective, safe, and convenient external therapy of traditional Chinese medicine for CARAS.
Methods
A total of 92 children aged 6–14 years with CARAS in remission will be randomly assigned (1:1) to either the control group (conventional medication) or the intervention group (conventional medication plus pediatric Tuina). The intervention will be administered three times weekly for 4 weeks, followed by a 24-week follow-up. The primary outcome measure is the Pediatric Rhinoconjunctivitis Quality of Life Questionnaire (PRQLQ) score. Secondary outcomes include the Childhood Asthma Control Test (C-ACT) / Asthma Control Test (ACT) score and traditional Chinese medicine (TCM) symptom scores. Safety will be assessed by monitoring any adverse events during the treatment period.
Discussion
This study will provide evidence for the efficacy and safety of pediatric Tuina in improving CARAS symptoms and quality of life in children. Clinical trial registration https://itmctr.ccebtcm.org.cn/mgt/project/view/1966089236985806848 , identifier [ITMCTR2025001712].
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Jing'an, Shanghai, China.
- School of Acupuncture-Moxibustion and Tuina, Shanghai University of Traditional Chinese Medicine, Pudong, Shanghai, China.
- Community Health Service Center of Nanhui New Town, Pudong, Shanghai, China.
Zitieren
APA
Chia, X. Y., Cai, J., Dai, D., Ji, Q., Liu, S., Wang, W., Si, M., Yang, Y., Lu, P., Wang, X., Dang, S., Zhong, Y., Wang, S., Wang, G., & Xiao, B. (2026). Efficacy and safety of Tuina therapy for children with combined allergic rhinitis and asthma syndrome in remission: a randomized controlled trial protocol. Frontiers in Medicine, 13. https://doi.org/10.3389/fmed.2026.1854540
Vancouver
Chia XY, Cai J, Dai D, Ji Q, Liu S, Wang W, et al. Efficacy and safety of Tuina therapy for children with combined allergic rhinitis and asthma syndrome in remission: a randomized controlled trial protocol. Frontiers in Medicine. 2026;13. doi:10.3389/fmed.2026.1854540
BibTeX
@article{Chia2026,
author = {Chia, Xin Yun and Cai, Junhao and Dai, Dan and Ji, Qing and Liu, Shijian and Wang, Wenyi and Si, Mengran and Yang, Yan and Lu, Ping and Wang, Xiaoqiu and Dang, Sijie and Zhong, Yi and Wang, Shuxia and Wang, Guimao and Xiao, Bin},
title = {Efficacy and safety of Tuina therapy for children with combined allergic rhinitis and asthma syndrome in remission: a randomized controlled trial protocol},
journal = {Frontiers in Medicine},
year = {2026},
volume = {13},
doi = {10.3389/fmed.2026.1854540}
}
EUVIMED